SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Neurogen (NRGN)
An SI Board Since June 1996
Posts SubjectMarks Bans Symbol
523 35 0 NRGN
Emcee:  Terry McCormick Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
123 Phase II on anti-obesity is to start in the next month or so. Pfizer is doing phbolton-10/17/1997
122 currently sitting on huge support at 24 ... 50-day ma ... late June peak head Thomas M.-10/17/1997
121 Mark Lampert has been buying NRGN since it was below 10. However, he has boughThomas M.-10/10/1997
120 I first heard about Lampert in a Barron's interview back in August, 1996BulbaMan-10/10/1997
119 Thanks Marty. I don't venture into Biotech much. But I like tracking sharpThorr-10/9/1997
118 For my money, BVF and its most prominent partner, Mark Lampert, are the bestBulbaMan-10/9/1997
117 Thorr: All I know about BVF is from the NRGN links that I've posted here eaphbolton-10/9/1997
116 Do you know anything about BVF? I have heard Mark is pretty sharp. It seems HThorr-10/8/1997
115 from the 13D: "(a) BVF beneficially owns 639,920 shares of the Stock, Partphbolton-10/5/1997
114 Thomas: the call prices basically suck at the moment, maybe if it stays here fphbolton-10/1/1997
113 Good call, there's big resistance here. The BTK is starting to correct, afThomas M.-10/1/1997
112 27? Highest close in quite sometime. I guess no news is good news. May buy sphbolton-9/30/1997
111 The NRGN anti-obesity drug is now entirely in the hands of Pfizer who will do tphbolton-9/18/1997
110 The Neurogen NPY obesity drug now has a slight time advantage compared to compeNeuroInvestment-9/18/1997
109 hit 26 briefly ... sliding back to test the old peak at 24 ... another buying oThomas M.-9/18/1997
108 Smith Barney recomends Neuogen as Venture Buy::::that is all that printed::::prRobert C. Petersen-9/18/1997
107 The FDA will be more cautious, but I still think approval will be faster now thkathleen-9/18/1997
106 just a guess, but it seems the opposite would be more likely: that after the feVolcano888-9/18/1997
105 I think the run up was caused by the withdrawal of Redux & fenfluramine. I kathleen-9/18/1997
104 well, big move up to 24 11/16 which is the highest close since october 96. alsphbolton-9/17/1997
103 the current, Aug 22, issue of Science has an interesting recap of the numerous phbolton-8/29/1997
102 Tom, Don't know if this fits your criteria, but have your friend look a Robert C. Petersen-8/22/1997
101 Have your friend study the Centocor/XOMA patent litigation and the eventual outscaram(o)uche-8/21/1997
100 I have a friend in law school who is looking for a topic for a research paper. Thomas M.-8/21/1997
99 kathleen: some patents are so vague that its hard to tell what they are even afphbolton-8/14/1997
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News